LENSAR (LNSR) earnings

Results to: Jun 2026
Latest analysed call: Jun 2026 (Q2 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

LENSAR earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	16.5 $ million	+18.4% YoY	Quarterly, as filed	Quarter to Jun 2026	Revenue from operations as filed.
Operating margin	12.9 %	+58.1 pts YoY	Operating profit / revenue	Quarter to Jun 2026	For the quarter; a change is in percentage points.
Net profit	3.5 $ million	—	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Price

$5.75 −0.86% · −$0.05

Last close Oct 19, 2026 · US · USD

Performance −51.5% 1Y

1Y: $11.85 on 17 Oct 2025 → $5.75. High $12.73 (30 Jan 2026), low $5.01 (31 Jul 2026).

Previous close: $5.8
52-week range: $5.01 – $12.73
One year: −53.18%

Overview

Symbol: LNSR
Sector: Health Care
Exchange: US
Currency: USD

Financials

What the filings say

Net profit, year on year: +300% (quarter to jun 2026 against jun 2025).

In $ million. Oldest period first.

Line item	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	14	17	14	14	14	16	13	16
Operating profit	-1	-1	-6	-6	-8	-5	2	2
Operating margin	−9.2%	−7.7%	−40.9%	−45.1%	−53.0%	−30.7%	16.7%	12.9%
Net profit	-2	-19	-27	-2	-4	-1	36	4
EPS ($ per share)	-0.13	—	-2.32	-0.15	-0.31	—	1.56	0.14

Source: Inve data · income statement, quarterly · to Jun 2026

In $ million. Oldest period first.

Line item	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity capital	0	0	0	0	0	0	0
Reserves	-38	-58	-78	-98	-112	-143	-178
Total liabilities	65	12	12	14	22	48	84
Fixed assets	1	1	1	1	1	1	1
Investments	—	—	—	—	3	6	5
Total assets	35	79	66	56	70	66	71

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	-13	-14	-9	-15	-10	-2	-15
Cash from investing	-2	-0	-0	-0	-4	-2	1
Cash from financing	16	50	0	-2	20	0	10
Net cash flow	1	36	-9	-17	6	-4	-3
Capital expenditure	-0	-0	-0	-0	-0	-0	-0
Free cash flow	-13	-14	-9	-15	-10	-2	-15

Source: Inve data · cash flow · to Dec 2025

Insider filings

21 filings between Jan 11, 2026 and Jun 3, 2026.

Open market

decisions to buy or sell

Nobody bought or sold LNSR on the open market in this window. The filings below are 10 awards, 1 option exercise, 7 tax withholdings and 3 other filings.

Compensation

not trading decisions

10: Award — granted as compensation
1: Option exercise — converted options into shares
7: Tax withheld — shares kept back by the company to cover tax

Latest filings (35)

Date	Insider	What	Shares	Value
Jun 3, 2026	CURTIS NICHOLAS T Chief Executive Officer	Award	130,662	$0
Jun 3, 2026	LINK WILLIAM J PHD Director	Award	17,421	$0
Jun 3, 2026	LINDSTROM RICHARD L MD Director	Award	17,421	$0
Jun 3, 2026	Winer Gary M Director	Award	17,421	$0
Jun 3, 2026	O'Farrell Elizabeth G. Director	Award	17,421	$0
Jun 3, 2026	WEISNER AIMEE S Director	Award	17,421	$0
Jun 3, 2026	Connaughton Alan B. Chief Operating Officer	Award	34,843	$0
Jun 3, 2026	Wong Kendra Principal Accounting Officer	Award	13,066	$0
Jun 3, 2026	ELLIS THOMAS B Director	Award	17,421	$0
Jun 3, 2026	HAMMER TODD B Director	Award	17,421	$0
May 6, 2026	Wong Kendra Principal Accounting Officer	Tax withheld	864	$4.7K
May 6, 2026	STAAB THOMAS R II Chief Financial Officer	Tax withheld	1,350	$7.3K
May 6, 2026	Connaughton Alan B. Chief Operating Officer	Tax withheld	2,739	$14.7K
May 6, 2026	CURTIS NICHOLAS T Chief Executive Officer	Other	0	$0
Mar 19, 2026	STAAB THOMAS R II Chief Financial Officer	Option exercise	5,500	$14.6K
Feb 18, 2026	STAAB THOMAS R II Chief Financial Officer	Tax withheld	1,076	$12.2K
Feb 18, 2026	CURTIS NICHOLAS T Chief Executive Officer	Other	0	$0
Feb 18, 2026	Connaughton Alan B. Chief Operating Officer	Tax withheld	2,392	$27.1K
Jan 11, 2026	Connaughton Alan B. Chief Operating Officer	Tax withheld	2,262	$26.2K
Jan 11, 2026	STAAB THOMAS R II Chief Financial Officer	Tax withheld	1,826	$21.1K
Jan 11, 2026	CURTIS NICHOLAS T Chief Executive Officer	Other	0	$0
May 23, 2025	LINDSTROM RICHARD L MD Director	Award	7,374	$0
May 23, 2025	LINK WILLIAM J PHD Director	Award	7,374	$0
May 23, 2025	Winer Gary M Director	Award	7,374	$0
May 23, 2025	O'Farrell Elizabeth G. Director	Award	7,374	$0
May 23, 2025	WEISNER AIMEE S Director	Award	7,374	$0
May 23, 2025	HAMMER TODD B Director	Award	7,374	$0
May 23, 2025	ELLIS THOMAS B Director	Award	7,374	$0
Feb 18, 2025	CURTIS NICHOLAS T Chief Executive Officer	Award	127,660	$0
Feb 18, 2025	Wong Kendra Principal Accounting Officer	Award	6,383	$0
Feb 18, 2025	STAAB THOMAS R II Chief Financial Officer	Award	12,766	$0
Feb 18, 2025	Connaughton Alan B. Chief Operating Officer	Award	37,234	$0
Jan 11, 2025	STAAB THOMAS R II Chief Financial Officer	Tax withheld	1,839	$15.2K
Jan 11, 2025	Wong Kendra Principal Accounting Officer	Tax withheld	1,132	$9.3K
Sep 3, 2024	Winer Gary M Director	Purchase	685	$3.1K

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for LENSAR, Inc.

Free account. Everything above stays public.

Write why you follow LENSAR, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading